November 1, 2011 — In postmenopausal breast cancer patients, bisphosphonates are commonly used to counter the adverse effects of aromatase inhibitors (AIs) on bone. Now there is a suggestion that the ...

“In the present study, we used multiple complementary approaches to evaluate the possible effects of zoledronic acid on cellular senescence.” Zoledronic acid has been found to reduce fracture risk and ...

Vancouver, British Columbia — A highly controlled retrospective analysis suggests that denosumab (Prolia) leads to greater reduction in fracture risk than does zoledronic acid (Reclast) among ...

In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from ...

Gonadotropin-releasing-hormone (GnRH) agonists are routinely used to manage recurrent nonmetastatic prostate cancer, but the therapy results in hypogonadism, which has adverse consequences including ...

Treatments were compared with the use of a Cox proportional-hazards regression model, with only the treatment group as a covariate, and the log-rank test was used for disease-free survival, recurrence ...

SEATTLE -- Treating osteogenesis imperfecta with the parathyroid hormone teriparatide followed by zoledronic acid, a bisphosphonate, failed to reduce the risk of fractures compared with standard ...

Financial and psychosocial impacts of adjuvant chemotherapy in older colorectal cancer patients. Background: Acute renal failure (ARF) is an adverse event associated with the use of zoledronic acid, ...

Clinician perceptions of care difficulty and quality of life for lung cancer patients: Results from the ECOG SOAPP study (E2Z02). Background: The majority of lymphoma patients receiving first-line ...